Daridorexant Tablets Should Not Be Split
Daridorexant (QUVIVIQ) tablets are film-coated formulations that should be swallowed whole and not cut, split, crushed, or chewed. 1
Pharmaceutical Formulation Considerations
The FDA labeling for daridorexant explicitly describes these as film-coated tablets with specific arc-triangle shapes 1:
- 25 mg: light purple, film-coated tablet
- 50 mg: light orange, film-coated tablet
Film-coated tablets are specifically designed to be swallowed intact. The coating serves multiple purposes including protecting the active ingredient from degradation, controlling release characteristics, and masking taste 1.
Why Splitting Is Problematic
Film-coated tablets lose their protective coating when split, which can lead to:
- Altered drug absorption and pharmacokinetics 2
- Exposure of the active ingredient to light, moisture, and air
- Unpredictable dosing due to unequal tablet fragments 3, 4
Research demonstrates that tablet splitting frequently results in significant dose variability, with studies showing 15-24% of split tablets falling outside acceptable weight and content uniformity specifications 3, 4. For medications requiring precise dosing, this variability can be clinically significant 5.
Dosing Alternatives
If a lower dose is needed, the 25 mg strength tablet is available and should be prescribed rather than attempting to split the 50 mg tablet 1. The FDA-approved dosing range is 25-50 mg taken whole, and specific clinical situations (moderate hepatic impairment, concomitant moderate CYP3A4 inhibitors) call for the 25 mg dose 1.
Clinical Caveat
Unlike some older sleep medications that are scored for splitting 6, daridorexant tablets are unscored and film-coated, which are clear pharmaceutical indicators that the manufacturer did not design these tablets for division 1.